$LRCX

Fernandes Neil J sold $2.4M of LRCX

Fernandes Neil J (Senior Vice President) sold 7,659 shares of LAM RESEARCH CORP (LRCX) at $309.60 ($2.37M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fernandes Neil J
Published Jun 2, 2026, 4:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 4:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LRCX
Neutral
medium confidence
Mentioned
$LRCX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRCXNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider liquidity/portfolio management but does not, by itself, change fundamentals or forward expectations.

02

Market read

Expect limited incremental impact; any trading reaction is likely sentiment-driven and short duration.

03

What to watch

Traders may overweight Form 4s; the plan’s pre-arranged nature and modest share count relative to float reduce predictive value.

Relevance 4/10Novelty 3/10Timing: Filed 2026-06-02; sale executed 2026-06-01.

Background

This is an SEC Form 4 insider transaction disclosure (officer/direct holdings) for LAM Research Corp.

Company-level read

Ticker impact

$LRCXNeutralMedium confidence
Context

LRCX SVP Fernandes Neil J sold 7,659 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any effect would be short-lived.

Evidence & confidence

The filing is a routine officer sale under a 10b5-1 plan, with no accompanying fundamental catalyst or guidance change reported.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide shock.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can still coincide with internal rebalancing needs; absence of buying may be less informative than the broader tape.

Key entities

  • LAM Research Corp

    Subject of the Form 4 insider sale by an officer under a 10b5-1 plan.

  • Fernandes Neil J

    Senior Vice President who sold 7,659 shares on 2026-06-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BACMed

US Futures Hold Steady Ahead of Inflation Report

US stock futures were stable on Wednesday ahead of the September inflation report. Bank of America shares fell over 2% after $1.2B in penalties from regulators. Memory stocks declined due to AI investment concerns and Chinese competition, with Micron down 4.6%. Financial stocks also dropped post-earnings, including Citigroup (-5.3%) and Wells Fargo (-2.6%).

$LRCXLow

Round Design Infringement Case Against Lam Research < Supply Chain < 기사본문

BCNC, a South Korean semiconductor component maker, was ordered by a Seoul court to stop producing and distributing certain edge-ring products, pay damages, and destroy existing inventory, following a design-right infringement lawsuit by Lam Research. The court partially dismissed Lam Research's claims. Both companies are also involved in separate patent disputes, with mixed rulings. BCNC plans to appeal the decision.

$LRCXMedAI 8/10

Lam Research Stocks Fall 2.1% as AI Spending Lifts Target 33%

Lam Research (LRCX) shares fell 2.42% to $325.81 on October 7, despite Cantor Fitzgerald raising its price target to $425 from $320. The company reported June-quarter revenue of $6.72 billion, up 15.1% from the prior quarter, with improved margins. Cantor's target suggests 30.4% upside, but shares are 106.68% above GF Value™ estimate of $157.64.

$LRCXHigh

TSMC Stock Hits Record High, Morgan Stanley Raises Lam Research Price Target

TSMC (TSM) stock hit a record high, nearing a $2.5T market cap, driven by AI chip demand. Morgan Stanley raised Lam Research's (LRCX) price target to $385, citing its share gains in advanced logic and expected December-quarter revenue of $9B, above consensus. The bank sees LRCX as a key beneficiary of TSMC's 2nm process advancements and increased capital expenditure share.